title: Fabry disease: results of the first UK hemodialysis screening study.
abstract: BACKGROUND
  Fabry disease is an X-linked lysosomal storage disorder in which deficiency of α-Galactosidase A (α-Gal A), leads to accumulation of glycosphingolipids in the vascular endothelium, kidneys and heart. Males with classical disease present in childhood, however some individuals with low levels of α-Gal A activity present atypically with adult onset renal impairment. Screening studies in patients with established end-stage renal failure (ESRF) suggest that up to 1.5% of patients have sub-normal α-Gal A levels. We used the dried blood spot (DBS) enzyme activity test to screen for undiagnosed Fabry disease in patients with ESRF.
  
  
  METHODS
  Male hemodialysis patients treated at a single UK center (n = 155) were screened using the DBS assay. In patients with low enzyme activity on DBS, α-Gal A activity was assessed in plasma and leucocytes.
  
  
  RESULTS
  8 of the 155 (5%) patients screened showed low enzyme activity on the DBS assay. Confirmatory testing of plasma and leucocyte α-Gal A activity showed normal activity in all cases tested, indicating a false positive DBS result.
  
  
  CONCLUSIONS
  This study is the first screening program in UK hemodialysis patients using the DBS test and did not identify any new cases of Fabry disease. In this cohort, the DBS enzyme assay had a false positive rate of 2.6%, emphasizing the need for validation with alternative techniques.
authors: Division of Renal Medicine, University of Cambridge Department of Medicine, and Addenbrooke's Hospital, Cambridge, UK. lizwallin@doctors.org.uk
authors: E F
authors: EF
authors: Wallin
authors: M R
authors: MR
authors: Clatworthy
authors: N R
authors: NR
authors: Pritchard